medigraphic.com

2021, Number 3

<< Back Next >>

Enf Infec Microbiol 2021; 41 (3)

Prevalence and correlation of IgG in patients infected by SARS-COV2 attended at Hospital Dr. Santiago Ramón y Cajal, ISSSTE in Durango

Galván MME, Morales CME, De la Hoya FC, Godínez SHA, Gálvez ALA, Carreón RGD, Ortega MME

Language: Spanish
References: 17
Page: 102-106
PDF size: 255.95 Kb.


ABSTRACT

Introduction. In the immune system there are two types of responses: rapid and unspecified innate immune response, and one adaptive response, slower but capable of creating memory.
Objective. To identify the prevalence of the igg in sars-cov-2 infected patients at ISSSTE Hospital in Durango.
Material and methods. Descriptive, observational, cross-sectional study; IiG concentration was measured in 33 sars-cov-2 infected patients, the chemiluminescence method was used in the Architect i 2000 sr®; a concentration ≥1.4 was considered positive, it was expressed in conventional units. The SPSS v24, descriptive statistics, ji2 of Bartlett, t of student, “r” of Pearson with ic95% and p‹0.05 were used as a reference point. The information obtained was kept anonymous.
Results. An media of 42.7 years was obtained, out of which the 60.6% were male, the media IgG concentration was 3.8 conventional units, symptoms persisted 9.5 days, and between the beginning of the symptoms and sampling, 104.2 days elapsed; the 87.8% of the patients had symptoms and 86.2% of them IgG was detected. There was a positive correlation between IgG concentration and duration of symptoms, this being significant.
Conclusions. igg concentrations will depend on how many days the symptoms last, there were patients that despite presenting symptoms, IgG was no longer detected for 104 days, this also happened with patients classified as asymptomatic.


REFERENCES

  1. Zeng, F., Dai, C., Cai, P., Wang, J., Xu, L., Li, J., Hu, G., Wang, Z., Zheng, F. y Wang, L., “A comparison study of sars-cov-2 igg antibody between male and female covid-19 patients: a possible reason underlying different outcome between sex”, J Med Virol, 2020, 92 (10): 2050-2054.

  2. Marklund, E., Leach, S., Axelsson, H., Nyström, K., Norder, H., Bemark, M. et al., “Serum- igg responses to sars-cov-2 after mild and severe covid-19 infection and analysis of igg non-responders”, plos One, 2020, 15 (10).

  3. Chowdhury, M.A., Hossain, N., Kashem, M.A., Shahid, M.A. y Alam, A., “Immune response in covid-19: a review”, J Infect Public Health, 2020, 13 (11): 1619-1629.

  4. Chaussabel, D., Pascual, V. y Banchereau, J., “Assessing the human immune system through blood transcriptomics”, bmc Biol, 2010, 8: 84.

  5. Who, “who coronavirus disease (covid-19) dashboard”, 2020. Disponible en: https://covid19.who.int/.

  6. Post, N., Eddy, D., Huntley, C., Van Schalkwyk, M.C.I., Shrotri, M., Leeman, D., Rigby, S., Williams, S.V., Bermingham, W.H., Kellam, P., Maher, J., Shields, A.M., Amirthalingam, G., Peacock, S.J. e Ismail, S.A., “Antibody response to sars-cov-2 infection in humans: a systematic review”, plos One, 2020, 15 (12).

  7. Anderson, D.E., Tan, C.W., Chia, W.N., Young, B.E., Linster, M., Low, J.H, et al., “Lack of cross-neutralization by sars patient sera towards sars-cov-2”, Emerg Microbes Infect, 2020, 9 (1): 900-902.

  8. Huang, A.T., García-Carreras, B., Hitchings, M.D.T., Yang, B., Katzelnick, L., Rattigan, S.M. et al., “A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease”, medRxiv [preprint], 2020, 2020.04.14.20065771.

  9. Kellam, P. y Barclay, W., “The dynamics of humoral immune responses following sars-cov-2 infection and the potential for reinfection”, J Gen Virol, 2020, 101 (8): 791- 797.

  10. Zost, S.J., Gilchuk, P., Case, J.B., Binshtein, E., Chen, R.E., Nkolola, J.P. et al., “Potently neutralizing and protective human antibodies against sars-cov-2”, Nature, 2020, 584 (7821): 443-449.

  11. Le Bert, N., Tan, A.T., Kunasegaran, K., Tham, C.Y.L., Hafezi, M., Chia, A. et al., “sars-cov-2-specific t cell immunity in cases of covid-19 and sars, and uninfected controls”, Nature, 2020, 584 (7821): 457-462.

  12. Robbiani, D.F., Gaebler, C., Muecksch, F., Lorenzi, J.C.C., Wang, Z., Cho, A. et al., “Convergent antibody responses to sars-cov-2 in convalescent individuals”, Nature, 2020, 584 (7821): 437-442.

  13. Tan, Y., Liu, F., Xu, X., Ling, Y., Huang, W., Zhu, Z. et al., “Durability of neutralizing antibodies and t-cell response post sars-cov-2 infection”, Front Med, 2020, 14 (6): 746- 751.

  14. Speletas, M., Kyritsi, M.A., Vontas, A., Theodoridou, A., Chrysanthidis, T., Hatzianastasiou, S. et al., “Evaluation of two chemiluminescent and three elisa immunoassays for the detection of sars-cov-2 igg antibodies: implications for disease diagnosis and patients’ management”, Front Immunol, 2020, 11.

  15. Long, Q.X., Tang, X.J., Shi, Q.L., Li, Q., Deng, H.J., Yuan, J. et al., “Clinical and immunological assessment of asymptomatic sars-cov-2 infections”, Nat Med, 2020, 26 (8): 1200-1204.

  16. Figueiredo-Campos, P., Blankenhaus, B., Mota, C., Gomes, A., Serrano, M., Ariotti, S. et al., “Seroprevalence of anti-sars-cov-2 antibodies in covid-19 patients and healthy volunteers up to 6 months post disease onset”, Eur J Immunol, 2020, 50 (12): 2025-2040.

  17. Legros, V., Denolly, S., Vogrig, M., Boson, B., Siret, E., Rigaill, J. et al., “A longitudinal study of sars-cov-2-infected patients reveals a high correlation between neutralizing antibodies and covid-19 severity”, Cell Mol Immunol, 2021, 6: 1-10.




2020     |     www.medigraphic.com